Proteon Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results
March 20, 2015 07:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 20, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 35th Annual Healthcare Conference on March 4th
February 26, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Ring the Nasdaq Stock Market Opening Bell on February 9th
February 06, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference February 9th
February 05, 2015 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease
January 08, 2015 16:30 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference December 11th
December 08, 2014 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2014 Financial Results
November 25, 2014 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces the Closing of Initial Public Offering and the Underwriters' Option to Purchase Additional Shares
November 24, 2014 08:00 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel Nicolaus 2014 Healthcare Conference November 18th
November 17, 2014 08:49 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics Announces Pricing of Initial Public Offering
October 21, 2014 19:36 ET
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc., a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and...